ArticleCancer biology & therapy2017
Enhanced procoagulant activity of platelets after chemotherapy in non-small cell lung cancer.
Article in Cancer biology & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Clinical features of pulmonary embolism in patients with lung cancer: A meta-analysis.PloS one · 2019Pooled it
- Longitudinal dynamics of hemostatic biomarkers in patients with cancer receiving immune checkpoint inhibitors vs chemotherapy: results from the Vienna CAT-BLED study.Research and practice in thrombosis and haemostasis · 2025Article
- Hypercoagulable state and effect of low-molecular-weight heparin prophylaxis on coagulation after lung cancer resection: results from thrombo-elastography.General thoracic and cardiovascular surgery · 2025Article
- Uniform impact on individual megakaryocytes is essential for efficient in vitro platelet production.Scientific reports · 2025Article
- The Basic Principles of Pathophysiology of Venous Thrombosis.International journal of molecular sciences · 2024Review
- Prophylaxis with abemaciclib delays tumorigenesis in dMMR mice by altering immune responses and reducing immunosuppressive extracellular vesicle secretion.Translational oncology · 2024Article
- Selective but not pan-CDK inhibition abrogates 5-FU-driven tissue factor upregulation in colon cancer.Scientific reports · 2024Article
- Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms.Frontiers in cell and developmental biology · 2023Review
- Dual Roles of Lactate in EGFR-TKI-Resistant Lung Cancer by Targeting GPR81 and MCT1.Journal of oncology · 2022Article
- Risk Factors and Prediction Models for Venous Thromboembolism in Ambulatory Patients with Lung Cancer.Healthcare (Basel, Switzerland) · 2021Review
- Cancer Therapy-Associated Thrombosis.Arteriosclerosis, thrombosis, and vascular biology · 2021Review
- Chemotherapy induced changes to fibrin clots properties in lung cancer: is it favorable?Journal of thoracic disease · 2019Article
- The Role of Platelets in the Tumor-Microenvironment and the Drug Resistance of Cancer Cells.Cancers · 2019Review
- Review
- Platelet-Derived Microparticles are an Important Biomarker in Patients with Cancer-Associated Thrombosis.International journal of general medicine · 2019Article
- Altered fibrin clot properties in advanced lung cancer: impact of chemotherapy.Journal of thoracic disease · 2018Article
- Lung Cancer and Pulmonary Embolism: What Is the Relationship? A Review.Journal of Cancer · 2018Review
- POLE: Development and Validation of a Pulmonary Embolism Prediction Model in Lung Cancer.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The procoagulant status of patients with non-small cell lung cancer (NSCLC) after chemotherapy is poorly characterized and the role of platelets in hypercoagulative state of NSCLC is unknown. The aim of this study was to evaluate the procoagulant activity (PCA) of platelets in NSCLC before and after chemotherapy. The subjects were 52 patients newly diagnosed with NSCLC. The patients had decreased clotting time compared with healthy subjects, and the thrombin-antithrombin complex increased 2.5-fold after chemotherapy. Platelets in the patients after chemotherapy had enhanced phosphatidylserine (PS) exposure, and shortened coagulation time as well as increased thrombin and fibrin formation of platelets compared with those before chemotherapy. Platelet-derived microparticles increased 2-fold at day 1 and peaked at day 2 post-chemotherapy. Treatment of cisplatin in vitro also resulted in upregulated intrinsic FXa and thrombin formation on platelets with a dose-dependent manner. Platelets treated with aspirin significantly decreased PCA. However, lactadherin blocked PS and inhibited the PCA approximately by 70%. Seven days after chemotherapy, PCA of platelets restored to the baseline as that before chemotherapy, indicating that within a week of chemotherapy patient platelets are highly procoagulant and effective intervention should be taken in case of thrombosis. Our results suggested that platelets after chemotherapy had elevated PCA and may contribute to the hypercoagulative state of NSCLC. Prophylactic anti-coagulant combined with anti-platelet therapy may play an inhibitory role in thrombotic complications in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.